Search results for "positron"

showing 10 items of 1346 documents

18F-FDG PET-Derived Tumor Blood Flow Changes After 1 Cycle of Neoadjuvant Chemotherapy Predicts Outcome in Triple-Negative Breast Cancer

2016

International audience; Previous studies have suggested that early changes in blood flow (BF) in response to neoadjuvant chemotherapy and evaluated with 150-water are a surrogate biomarker of outcome in women with breast cancer. This study investigates, in the triple-negative breast cancer subtype, the prognostic relevance of tumor BF changes (Delta BF) in response to chemotherapy, assessed using a short dynamic F-18-FDG PET acquisition. Methods: Forty-six consecutive women with triple-negative breast cancer and an indication for neoadjuvant chemotherapy were prospectively included. Women benefited from a baseline F-18-FDG PET examination with a 2-min chest-centered dynamic acquisition, sta…

Oncologymedicine.medical_specialtyPrognostic-FactorsBevacizumabSurvival[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingmedicine.medical_treatment[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineperfusion[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerInternal medicineMedicineblood flowRadiology Nuclear Medicine and imaging[ SDV.IB ] Life Sciences [q-bio]/BioengineeringTomography[ SDV.IB.IMA ] Life Sciences [q-bio]/Bioengineering/ImagingNeoadjuvant therapyTriple-negative breast cancerSubtypesMarkersChemotherapytriple-negativemedicine.diagnostic_testbusiness.industryTriple Negative Breast Neoplasmsmedicine.disease3. Good healthBevacizumabPETMetabolismPositron emission tomography030220 oncology & carcinogenesisBiomarker (medicine)Pathological Response[SDV.IB]Life Sciences [q-bio]/BioengineeringAngiogenesisTherapybusinessmedicine.drug
researchProduct

[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy

2007

To evaluate, in breast cancer patients treated by neoadjuvant chemotherapy, the predictive value of reduction in FDG uptake with regard to complete pathological response (pCR).Forty-seven women with non-metastatic, non-inflammatory, large or locally advanced breast cancer were included. Tumour uptake of FDG was evaluated before and after the first course of neoadjuvant chemotherapy. Four indices were used: maximal and average SUV without or with correction by body surface area and glycaemia (SUV(max), SUV(avg), SUV(max-BSA-G) and SUV(avg-BSA-G), respectively). The predictive value of reduction in FDG uptake with respect to pCR was studied by logistic regression analysis. Relationships betwe…

Oncologymedicine.medical_specialtymedicine.medical_treatmentPathological responseAntineoplastic AgentsBreast Neoplasms[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineSensitivity and Specificity030218 nuclear medicine & medical imaging18f fdg pet[SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine03 medical and health sciences0302 clinical medicineBreast cancerFluorodeoxyglucose F18Internal medicinemedicineHumansRadiology Nuclear Medicine and imagingNeoadjuvant therapyComputingMilieux_MISCELLANEOUSChemotherapymedicine.diagnostic_testbusiness.industryFdg uptakeReproducibility of ResultsGeneral MedicineMiddle Agedmedicine.diseasePrognosisNeoadjuvant Therapy3. Good healthClinical trialTreatment OutcomePositron emission tomography030220 oncology & carcinogenesisPositron-Emission TomographyFemaleRadiopharmaceuticalsbusiness
researchProduct

Search for flavor-changing neutral current and lepton-flavor violating decays of D-0 -> l(+)l(-)

2004

We report on a search for the flavor-changing neutral current decays $\Dz\to e^+e^-$ and $\Dz\to\mu^+\mu^-$, and the lepton-flavor violating decay $\Dz\to e^\pm\mu^\mp$. The measurement is based on $122 {fb}^{-1}$ of data collected by the \babar detector at the PEP-II asymmetric $e^+e^-$ collider. No evidence is found for any of the decays. The upper limits on the branching fractions, at the 90 % confidence level, are $1.2\times 10^{-6}$ for $\Dz\to e^+e^-$, $1.3\times 10^{-6}$ for $\Dz\to\mu^+\mu^-$, and $8.1\times 10^{-7}$ for $\Dz\to e^\pm\mu^\mp$.

OptimizationParticle physicsLepton-flavor violating (LFV)Electron–positron annihilationBABARCharged particleGeneral Physics and Astronomy-Standard model (SM)Lambda baryon01 natural sciencesPARTICLE PHYSICS; PEP2; BABARHigh Energy Physics - ExperimentNONuclear physicsSilicon microstrip detector0103 physical sciencesPEP2010306 general physicsDETECTOR; BABAR; SLACDETECTORFlavorProbabilityPhysicsNeutral current010308 nuclear & particles physicsEnergy dissipationFlavor-changing neutral currentColliding beam acceleratorMicrostrip deviceHEPFlavor-changing neutral current (FCNC)Drift chamberPARTICLE PHYSICSHigh Energy Physics::ExperimentParticle detectorSLACLepton
researchProduct

Analytical results forO(αs)radiative corrections toe+e−→tt¯↑up to a given gluon energy cut

2009

We determine the O({alpha}{sub s}) radiative corrections to polarized top quark pair production in e{sup +}e{sup -} annihilations with a specified gluon energy cut. We write down fully analytical results for the unpolarized and polarized O({alpha}{sub s}) cross sections e{sup +}e{sup -}{yields}tt(G) and e{sup +}e{sup -}{yields}tt{sup {up_arrow}}(G) including their polar orientation dependence relative to the beam direction. In the soft-gluon limit we recover the usual factorizing form known from the soft-gluon approximation. In the limit when the gluon energy cut takes its maximum value we recover the totally inclusive unpolarized and polarized cross sections calculated previously. We provi…

Orientation (vector space)PhysicsNuclear and High Energy PhysicsParticle physicsTop quarkAnnihilationPair productionElectron–positron annihilationHigh Energy Physics::PhenomenologyRadiative transferEnergy (signal processing)GluonPhysical Review D
researchProduct

2019

The widespread use of 68Ga for positron emission tomography (PET) relies on the development of radiopharmaceutical precursors that can be radiolabelled and dispensed in a simple, quick, and convenient manner. The DATA (6-amino-1,4-diazapine-triacetate) scaffold represents a novel hybrid chelator architecture possessing both cyclic and acyclic character that may allow for facile access to 68Ga-labelled tracers in the clinic. We report the first bifunctional DATA chelator conjugated to [Tyr3]octreotide (TOC), a somatostatin subtype 2 receptor (SST2)-targeting vector for imaging and functional characterisation of SSTR2 expressing tumours. The radiopharmaceutical precursor, DATA-TOC, was synthe…

PET-CTmedicine.diagnostic_test010405 organic chemistrybusiness.industrySomatostatin receptorRadiochemistry010402 general chemistry01 natural sciences0104 chemical sciencesPharmacokineticsIn vivoPositron emission tomographyMedicineSomatostatin receptor 2Radiology Nuclear Medicine and imagingbusinessReceptormCherryEJNMMI Research
researchProduct

Reply: “The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer”

2019

PET-CTmedicine.diagnostic_testbusiness.industryUrology68ga psmaMagnetic resonance imagingPet imagingManagement of prostate cancerPositron emission tomographymedicineHaloNuclear medicinebusinessScatter correctionUrology
researchProduct

In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA5.SA.FAPi and DOTA.SA.FAPi

2021

Recently, the first squaramide-(SA) containing FAP inhibitor-derived radiotracers were introduced. DATA5m.SA.FAPi and DOTA.SA.FAPi with their non-radioactive complexes showed high affinity and selectivity for FAP. After a successful preclinical study with [68Ga]Ga-DOTA.SA.FAPi, the first patient studies were realized for both compounds. Here, we present a new squaramide-containing compound targeting FAP, based on the AAZTA5 chelator 1,4-bis-(carboxylmethyl)-6-[bis-(carboxymethyl)-amino-6-pentanoic-acid]-perhydro-1,4-diazepine. For this molecule (AAZTA5.SA.FAPi), complexation with radionuclides such as gallium-68, scandium-44, and lutetium-177 was investigated, and the in vitro properties of…

PREPPharmaceutical ScienceAcetatesLutetiumLigands030218 nuclear medicine & medical imagingAnalytical ChemistrySerinechemistry.chemical_compoundQD241-4410302 clinical medicineFibroblast activation protein alphaPositron Emission Tomography Computed TomographyDrug Discoverylutetium-177AAZTA; scandium-44; lutetium-177; FAP; SA; DPP; PREPQuinineChemistrySerine EndopeptidasesAzepinesscandium-44ChemistryChemistry (miscellaneous)030220 oncology & carcinogenesisMolecular MedicineSelectivityDPPGallium RadioisotopesConjugated systemArticleHeterocyclic Compounds 1-Ring03 medical and health sciencesSAEndopeptidasesHumansDOTAChelationPhysical and Theoretical ChemistryBiologyAAZTARadioisotopesOrganic ChemistrySquaramideMembrane ProteinsFAPFibroblastsCombinatorial chemistryIn vitroRadiopharmaceuticalsScandiumMolecules
researchProduct

Imaging standardisation in metastatic colorectal cancer: a joint EORTC-ESOI-ESGAR expert consensus recommendation

2022

Background: Treatment monitoring in metastatic colorectal cancer (mCRC) relies on imaging to evaluate the tumor burden. Response Evaluation Criteria in Solid Tumors (RECIST) provide a framework on reporting and interpretation of imaging findings yet offer no guidance on a standardized imaging protocol tailored to mCRC patients. Imaging protocol heterogeneity remains a challenge for the reproducibility of conventional imaging endpoints and is an obstacle for research on novel imaging endpoints. Patients and methods: Acknowledging the recently highlighted potential of radiomics and artificial intelligence (AI) tools as decision support for patient care in mCRC, a multidisciplinary, internatio…

PROTOCOLCancer ResearchPositron emission tomographyArtificial intelligenceConsensusBEVACIZUMABMedizinImagingCancer -- ImagingHumansCRITERIAColon (Anatomy) -- Cancer -- TomographyComputed tomographyScience & TechnologyRadiomicsRectal NeoplasmsAbdomen -- Radiography -- Case studiesColon (Anatomy) -- Cancer -- TreatmentReproducibility of ResultsAbdomen -- Radiography -- StandardsOPEN-LABELColorectal cancerArtificial intelligence Standardisation Colorectal cancer Computed tomography Imaging Positron emission tomography RadiomicsOncologyColonic NeoplasmsSURVIVALStandardisationLife Sciences & Biomedicine
researchProduct

Search for pair production of heavy objects in 4-jet events at sqrt {s}$=130-136 GeV

1996

Results are presented of a search for pair production of heavy objects decaying into four hadronic jets, as expected for example from associated or pair production of MSSM Higgs bosons, hA or H$^+$H$^-$, using a data sample of $5.9\,$pb$^{-1}$ of $e^+ e^-$ collisions at $\sqrt{s}=130$-$136\,{\mathrm {GeV}}$ collected with the DELPHI detector at LEP in November 1995. The data and expectations from standard processes agree after four-jet selections. An analysis based on $b$-tagging finds no hA candidate with high mass. A study optimized to search for H$^+$H$^-$ events with mass in the 40-50$\,{\mathrm{GeV}}/c^2$ range also finds no candidate. Finally a comparison is made with a recent ALEPH a…

Particle physicsAlephPhysics and Astronomy (miscellaneous)ENERGIESElectron–positron annihilationHadronHIGGS BOSONSJet (particle physics)Partícules (Física nuclear)DECAYSNuclear physics[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Detectors de radiacióBosonDELPHIPhysicsHigh Energy Physics::PhenomenologySupersymmetryLARGE ELECTRON POSITRON COLLIDERHIGGS BOSONS; ENERGIES; DECAYSPair productionPARTICLE PHYSICS; LARGE ELECTRON POSITRON COLLIDER; DELPHIHiggs bosonPARTICLE PHYSICSHigh Energy Physics::ExperimentParticle Physics - Experiment
researchProduct

Search for Higgs bosons decaying to WW in e(+)e(-) stope collisions at LEP

2006

A search for Higgs bosons produced in association with a fermion pair, and decaying to WW, is performed with the data collected by the ALEPH detector at centre-of-mass energies ranging from 191 to 209 GeV. The data correspond to an integrated luminosity of 453.2 pb^-1. Thirteen exclusive selections are developed according to the different final state topologies. No statistically significant evidence for a Higgs boson decaying into a WW pair has been found. An upper limit is derived, as a function of the Higgs boson mass, on the product of the e+e- -> Hff cross section and the H -> WW branching ratio. The data on the search for H -> WW are combined with previously published ALEPH re…

Particle physicsAlephPhysics and Astronomy (miscellaneous)Electron–positron annihilationFOS: Physical sciences7. Clean energy01 natural sciencesHigh Energy Physics - ExperimentNuclear physicsHigh Energy Physics - Experiment (hep-ex)0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]010306 general physicsEngineering (miscellaneous)BosonPhysicsLuminosity (scattering theory)010308 nuclear & particles physicsBranching fractionHigh Energy Physics::PhenomenologyFermionFunction (mathematics)3. Good healthHiggs bosonHigh Energy Physics::ExperimentHiggs Boson Invariant Mass Higgs Boson Mass Time Projection Chamber Inant VariableParticle Physics - Experiment
researchProduct